Christopher Kiritsy
Director/Board Member bei PIERIS PHARMACEUTICALS, INC.
Vermögen: 3 660 $ am 31.03.2024
Profil
Christopher P.
Kiritsy is the founder of Arisaph Pharmaceuticals, Inc. (founded in 1999) and Precision Kapital LLC (founded in 2018).
At Arisaph Pharmaceuticals, he held the titles of President, Chief Executive Officer & Director from 2005 to 2018.
He is currently a Director at HTG Molecular Diagnostics, Inc. (since 2022) and an Independent Director at Pieris Pharmaceuticals, Inc. (since 2016).
He previously held positions such as Chairman at Avaxia Biologics, Inc., Associate Director-Product Development at the University of Oregon, Director at Melinta Subsidiary Corp., and CFO & Executive VP-Corporate Development at KOS Pharmaceuticals, Inc. Mr. Kiritsy holds an MBA from Boston University and an undergraduate degree from Bowdoin College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.06.2023 | 20 000 ( 0,02% ) | 3 660 $ | 31.03.2024 | |
| 01.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Christopher Kiritsy
| Unternehmen | Position | Beginn |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 20.09.2016 |
| HTG MOLECULAR DIAGNOSTICS, INC. | Director/Board Member | 27.01.2022 |
| Precision Kapital LLC | Founder | 01.01.2018 |
Ehemalige bekannte Positionen von Christopher Kiritsy
| Unternehmen | Position | Ende |
|---|---|---|
Arisaph Pharmaceuticals, Inc.
 Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Founder | 01.01.2018 |
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Director of Finance/CFO | 23.05.2005 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Director/Board Member | - |
| University of Oregon | Corporate Officer/Principal | - |
Avaxia Biologics, Inc.
 Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Chairman | - |
Ausbildung von Christopher Kiritsy
| Boston University | Masters Business Admin |
| Bowdoin College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
| Precision Kapital LLC |
